ADXN.NASDAQAddex Therapeutics LTD
Form 4: Addex Therapeutics Executive Receives Stock Grant
Sentiment:
Insider Transaction (Form 4)
Lenaic Nathanael Teyssedou, PRINCIPAL ACCOUNTING OFFICER of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.
Summary
- Disposition to the issuer: disposed of 37,770 Stock-option (Right to Buy) on September 2, 2026; holds 565,138 after (Direct).
- Grant/award: acquired 37,770 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 59,530 Stock-option (Right to Buy) on September 2, 2026; holds 543,378 after (Direct).
- Grant/award: acquired 59,530 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 10,000 Stock-option (Right to Buy) on September 2, 2026; holds 592,908 after (Direct).
- Grant/award: acquired 10,000 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 30,000 Stock-option (Right to Buy) on September 2, 2026; holds 572,908 after (Direct).
- Grant/award: acquired 30,000 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 65,620 Stock-option (Right to Buy) on September 2, 2026; holds 537,288 after (Direct).
- Grant/award: acquired 65,620 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 90,529 Stock-option (Right to Buy) on September 2, 2026; holds 512,379 after (Direct).
- Grant/award: acquired 90,529 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 208,974 Stock-option (Right to Buy) on September 2, 2026; holds 393,934 after (Direct).
- Grant/award: acquired 208,974 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
- Disposition to the issuer: disposed of 100,485 Stock-option (Right to Buy) on September 2, 2026; holds 502,423 after (Direct).
- Grant/award: acquired 100,485 Stock-option (Right to Buy) on September 2, 2026; holds 602,908 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lenaic Nathanael Teyssedou — Officer (PRINCIPAL ACCOUNTING OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 37,770 | — | — | 565,138 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 37,770 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 59,530 | — | — | 543,378 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 59,530 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 10,000 | — | — | 592,908 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 10,000 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 30,000 | — | — | 572,908 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 30,000 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 65,620 | — | — | 537,288 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 65,620 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 90,529 | — | — | 512,379 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 90,529 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 208,974 | — | — | 393,934 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 208,974 | — | — | 602,908 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 100,485 | — | — | 502,423 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 100,485 | — | — | 602,908 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-02 | Disposition to the issuer (37,770 shares) |
| 2026-09-02 | Grant/award (37,770 shares) |
| 2026-09-02 | Disposition to the issuer (59,530 shares) |
| 2026-09-02 | Grant/award (59,530 shares) |
| 2026-09-02 | Disposition to the issuer (10,000 shares) |
| 2026-09-02 | Grant/award (10,000 shares) |
| 2026-09-02 | Disposition to the issuer (30,000 shares) |
| 2026-09-02 | Grant/award (30,000 shares) |
| 2026-09-02 | Disposition to the issuer (65,620 shares) |
| 2026-09-02 | Grant/award (65,620 shares) |
| 2026-09-02 | Disposition to the issuer (90,529 shares) |
| 2026-09-02 | Grant/award (90,529 shares) |
| 2026-09-02 | Disposition to the issuer (208,974 shares) |
| 2026-09-02 | Grant/award (208,974 shares) |
| 2026-09-02 | Disposition to the issuer (100,485 shares) |
| 2026-09-02 | Grant/award (100,485 shares) |
Keywords
insider transaction, Form 4, ADXN, Addex Therapeutics Ltd., neutral, Lenaic Nathanael Teyssedou
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.